A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)

NCT04630028 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

112

Enrollment

INDUSTRY

Sponsor class

Conditions

Colitis, Ulcerative

Interventions

DRUG: Ustekinumab Dose Based on BSA and Body Weight
DRUG: Matching Placebo

Sponsor

Janssen Research & Development, LLC